8-K: Akero Therapeutics Announces Third Quarter 2024 Financial Results and Provides Clinical Program Update

Akero Therapeutics reported its third quarter 2024 financial results and provided an update on its clinical programs, including the dosing of the first patient in the Phase 3 SYNCHRONY Outcomes study.

Summary

• Akero Therapeutics announced its third quarter 2024 financial results, reporting a net loss of $72.7 million, or $1.05 per share.
• The company's cash, cash equivalents, and marketable securities totaled $787.1 million as of September 30, 2024.
• Research and development expenses for the quarter were $72.2 million, up from $38.6 million in the same period of 2023.
• General and administrative expenses were $9.5 million, compared to $8.0 million in the third quarter of 2023.
• The first patient was dosed in the Phase 3 SYNCHRONY Outcomes study for efruxifermin (EFX), a treatment for MASH.
• The Phase 3 SYNCHRONY program includes three ongoing trials evaluating EFX for pre-cirrhotic MASH (F2-F3) and compensated cirrhosis (F4).
• The Phase 2b SYMMETRY study is expected to report week 96 results in February 2025.
• Results for the SYNCHRONY Real-World study are expected in 2026, and the SYNCHRONY Histology study results are expected in the first half of 2027.
• Akero believes its current cash will fund the SYNCHRONY Histology and Real-World studies through their primary endpoints and its operating plan into the second half of 2027.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the progress in clinical trials and strong cash position, but tempered by the significant net loss and increased expenses. The company is making good progress but is still in the high risk clinical stage.

Positives

• The company has a strong cash position of $787.1 million.
• The Phase 3 SYNCHRONY program is progressing with all three studies actively enrolling patients.
• The Phase 2b SYMMETRY study is on track to report results in February 2025.
• Akero believes its current cash will fund operations into the second half of 2027.
• Efruxifermin (EFX) is showing promise as a potential treatment for MASH.

Negatives

• The company reported a net loss of $72.7 million for the third quarter of 2024.
• Research and development expenses have significantly increased to $72.2 million for the quarter.
• General and administrative expenses have also increased to $9.5 million for the quarter.
• The company is still in the clinical stage and not yet generating revenue from product sales.

Risks

• Clinical trial results may not be positive or may not lead to regulatory approval.
• The company may need to raise additional capital in the future.
• There are risks associated with the development and commercialization of new drugs.
• Regulatory developments in the United States and foreign countries could impact the company.
• The company's ability to execute on its strategy is subject to various risks and uncertainties.

Future Outlook

Akero believes its current cash will fund the SYNCHRONY Histology and Real-World studies through their primary endpoints and its operating plan into the second half of 2027. The company anticipates reporting results from the SYMMETRY study in February 2025, the SYNCHRONY Real-World study in 2026, and the SYNCHRONY Histology study in the first half of 2027.

Management Comments

• The third quarter of 2024 marked an important milestone for EFX with the first patient dosed in the Phase 3 SYNCHRONY Outcomes study, said Andrew Cheng, president and CEO.
• With this advancement, all three of our Phase 3 studies are actively enrolling furthering our assessment of the safety and efficacy of EFX and moving us closer to delivering a differentiated treatment option, if approved, to patients living with MASH.

Industry Context

This announcement is significant in the context of the growing need for effective treatments for MASH, a serious liver disease with limited treatment options. Akero's progress in Phase 3 trials positions them as a potential key player in this space, competing with other companies developing therapies for MASH.

Comparison to Industry Standards

• Akero's focus on MASH is aligned with the industry's increasing attention to non-alcoholic fatty liver disease (NAFLD) and its more severe form, MASH.
• The company's Phase 3 program is comparable to other companies such as Madrigal Pharmaceuticals and Intercept Pharmaceuticals, which are also developing treatments for MASH.
• The reported cash position of $787.1 million is relatively strong compared to other clinical-stage biotech companies, providing a runway for continued development.
• The increase in R&D expenses is typical for a company advancing multiple clinical trials, and is in line with industry standards for companies in this stage of development.

Stakeholder Impact

• Shareholders may be encouraged by the clinical progress and strong cash position.
• Employees may be impacted by the increased workload associated with the ongoing clinical trials.
• Patients with MASH may benefit from the potential development of a new treatment option.
• Creditors may be reassured by the company's financial stability.

Next Steps

• Continue enrollment in the Phase 3 SYNCHRONY studies.
• Report week 96 results from the Phase 2b SYMMETRY study in February 2025.
• Report results from the SYNCHRONY Real-World study in 2026.
• Report results from the SYNCHRONY Histology study in the first half of 2027.

Key Dates

Keywords

Akero Therapeutics, efruxifermin, MASH, NASH, clinical trials, Phase 3, Phase 2b, liver disease, metabolic disease, biotechnology